During the past decade, National Ophthalmic Research Institute conducted 32 clinical trials. In the 10-year time frame, 32 clinical trials started and 22 clinical trials were completed, i.e. on average, 68.8% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 19 clinical trials were completed. i.e. 158.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "National Ophthalmic Research Institute" #1 sponsor was "Jaeb Center for Health Research" with 11 trials, followed by "Hoffmann-La Roche" with 10 trials sponsored, "Genentech, Inc." with 4 trials sponsored, "Kodiak Sciences Inc" with 4 trials sponsored and "Novartis Pharmaceuticals" with 4 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "National Ophthalmic Research Institute" #1 collaborator was "National Eye Institute (NEI)" with 11 trials as a collaborator, "National Institutes of Health (NIH)" with 6 trials as a collaborator, "Juvenile Diabetes Research Foundation" with 3 trials as a collaborator, "Regeneron Pharmaceuticals" with 3 trials as a collaborator and "Allergan" with 2 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "National Ophthalmic Research Institute" are "Diabetic Macular Edema" (15 trials), "Geographic Atrophy" (6 trials), "Macular Degeneration" (4 trials), "Diabetic Retinopathy" (3 trials) and "Age-Related Macular Degeneration" (2 trials). Many other conditions were trialed in "National Ophthalmic Research Institute" in a lesser frequency.

Most popular intervention types in "National Ophthalmic Research Institute" are "Drug" (35 trials), "Other" (13 trials), "Procedure" (5 trials), "Device" (3 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (9 trials), "Aflibercept" (5 trials), "Ranibizumab" (5 trials), "Faricimab" (4 trials) and "KSI-301" (4 trials). Other intervention names were less common.

The vast majority of trials in "National Ophthalmic Research Institute" are 40 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "National Ophthalmic Research Institute". undefined are not yet recruiting, 4 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 21 completed trials in National Ophthalmic Research Institute, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in National Ophthalmic Research Institute, 2 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 25 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".